rtCGM in the Hospital: Breaking Down Acute ICU and Non-ICU Experience and Best Practices
This continuing medical education activity is supported by an independent educational grant from Dexcom.
This activity is intended for primary care physicians, hospitalists, and critical care specialists.
The goal of this activity is to update hospital-based clinicians on the latest uses of real-time continuous glucose monitoring (rtCGM) in both the intensive care unit (ICU) and non-ICU settings, and to provide best practices that can be implemented to improve patient care and outcomes.
Upon successful completion of this activity, participants should:
- Have increased knowledge regarding the:
- Rationale for increased use of continuous glucose monitoring (CGM) and remote monitoring of blood glucose (BG) levels in the hospital setting
- Data supporting the use of CGM in the intensive care unit (ICU) and non-ICU inpatient settings
- Have greater competence related to
- Clinical use of rtCGM to improve patient outcomes in hospitalized patients
CONFLICT OF INTEREST POLICY/DISCLOSURE STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, faculty, and reviewers involved in the development of accredited content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control. Relationship information is accurate at the time of content development.
Medscape, LLC staff have disclosed that they have no relevant financial relationships.
In support of improving patient care, Medscape, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Medscape, LLC designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.50 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Aggregate participant data will be shared with commercial supporters of this activity.
This enduring material is approved for 1 year from the date of original release, November 12, 2021, to November 12, 2022.
This activity is accredited through Medscape. Click the link below to claim credit. You will be prompted to create a Medscape account and complete the post-test. If a satisfactory score on the post-test is achieved, Medscape will issue an AMA PRA Category 1 Credit(s)™ Certificate.
The educational activity presented above may involve simulated, case-based scenarios. The patients depicted in these scenarios are fictitious and no association with any actual patient, whether living or deceased, is intended or should be inferred. The material presented here does not necessarily reflect the views of Medscape, LLC, or any individuals or commercial entities that support companies that support educational programming on medscape.org. These materials may include discussion of therapeutic products that have not been approved by the US Food and Drug Administration, off-label uses of approved products, or data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal. Readers should verify all information and data before treating patients or employing any therapies described in this or any educational activity. A qualified healthcare professional should be consulted before using any therapeutic product discussed herein.
Athena Philis-Tsimikas, MD
Corporate Vice President
Scripps Whittier Diabetes Institute at Scripps Health
Director of Community Engagement
Scripps Research Translational Institute
La Jolla, California
Athena Philis-Tsimikas, MD, has disclosed the following relevant financial relationships:
- Served as an advisor or consultant for: Bayer; Lilly; Novo Nordisk; Sanofi
- Received grants for clinical research from: Abbott; Dexcom; Lilly; Novo Nordisk; Sanofi
Kathleen M. Dungan, MD, MPH
Associate Professor of Medicine
The Ohio State University
Division of Endocrinology, Diabetes, and Metabolism
Kathleen M. Dungan, MD, MPH, has disclosed the following relevant financial relationships:
- Served as an advisor or consultant for: Eli Lilly; Janssen; Novo Nordisk; Tolerion
- Received grants for clinical research from: Abbott; Novo Nordisk; Sanofi Aventis
Eileen R. Faulds, PhD, MS, RN, FNP-BC, CDE
Center for Healthy Aging, Self-Management, and Complex Care
The Ohio State University College of Nursing
The Ohio State University Wexner Medical Center
Eileen R. Faulds, PhD, MS, RN, FNP-BC, CDE, has disclosed the following relevant financial relationships:
- Other: Founder: AlControl
Guillermo Umpierrez, MD
Professor of Medicine
Division of Endocrinology, Metabolism
Emory University School of Medicine
Diabetes and Endocrinology
Grady Memorial Hospital
The opinions expressed are those of Dr Umpierrez and do not necessarily reflect the views of Emory University or Emory Healthcare. Dr Umpierrez's participation in this activity does not constitute or imply endorsement by Emory University or Emory Healthcare.
Guillermo Umpierrez, MD, has disclosed the following relevant financial relationships:
- Received grants for clinical research from: Grants to Emory University: AstraZeneca; Dexcom; Novo Nordisk